Rodrigo Dalmolin

Prof. Rodrigo Dalmolin

Federal University of Rio Grande do Norte - UFRN
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Biochemical Pharmacology
Verified
Journal Article
Closed access
Alfeu Zanotto-FilhoAlfeu Zanotto-Filho
Alfeu Zanotto-Filho
EBElizandra Braganhol
Elizandra Braganhol
RSRafael Schröder
Rafael Schröder
LSLuís Henrique T. de Souza
Luís Henrique T. de Souza
Rodrigo DalmolinRodrigo Dalmolin
Rodrigo Dalmolin
JMJosé Cláudio Fonseca Moreira
José Cláudio Fonseca Moreira

12 February 2018 in Critical Reviews in Toxicology
Verified
Journal Article
Closed access
ISIara Dantas de Souza
Iara Dantas de Souza
AAAbraão Silveira de Andrade
Abraão Silveira de Andrade
Rodrigo DalmolinRodrigo Dalmolin
Rodrigo Dalmolin
Lead is an important heavy metal used worldwide in several applications, especially in industry. People exposed to lead can develop a wide range of symptoms associated with lead poisoning. Many effects of lead poisoning are reported in the literature, showing a compromising of whole body health, with symptoms related to cardiovascular, immune, bone, reproductive, hematological, renal, gastrointestinal, and nervous system. However, the molecular lead targets as well as the pathways affected by lead poisoning are not completely described. The aim of this study was to construct a map of metabolic pathways impaired in lead poisoning by evaluating which biomolecules are directly affected by lead. Through manual literature curation, we identified proteins which physically interact with lead and subsequently determined the metabolic pathways those proteins are involved with. At total, we identified 23 proteins involved with heme synthesis, calcium metabolism, neurotransmission, among other biological systems, which helps to understand the wide range of lead-poisoning symptoms.

24 March 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YHYibin Hao
Yibin Hao
WWWei Wu
Wei Wu
FSFachun Shi
Fachun Shi
Rodrigo DalmolinRodrigo Dalmolin
Rodrigo Dalmolin
MYMing Yan
Ming Yan
WCWei Cao
Wei Cao
Long non-coding RNAs (lncRNAs) are pervasively transcribed in the genome. They have important regulatory functions in chromatin remodeling and gene expression. Dysregulated lncRNAs have been studied in cancers, but their role in esophageal squamous cell carcinoma (ESCC) remains largely unknown. We have conducted lncRNA expression screening and a genome-wide analysis of lncRNA and coding gene expression on primary tumor and adjacent normal tissue from four ESCC patients, tend to understand the functionality of lncRNAs in carcinogenesis of esopheagus in combination with experimental and bioinformatics approach. LncRNA array was used for coding and non-coding RNA expression. R program and Bioconductor packages (limma and RedeR) were used for differential expression and co-expression network analysis, followed by independent confirmation and functional studies of inferred onco-lncRNA ESCCAL-1 using quantitative real time polymerase chain reaction, small interfering RNA-mediated knockdown, apoptosis and invasion assays in vitro. The global coding and lncRNA gene expression pattern is able to distinguish ESCC from adjacent normal tissue. The co-expression network from differentially expressed coding and lncRNA genes in ESCC was constructed, and the lncRNA function may be inferred from the co-expression network. LncRNA ESCCAL-1 is such an example as a predicted novel onco-lncRNA, and it is overexpressed in 65% of an independent ESCC patient cohort (n = 26). More over, knockdown of ESCCAL-1 expression increases esophageal cancer cell apoptosis and reduces the invasion in vitro. Our study uncovered the landscape of ESCC-associated lncRNAs. The systematic analysis of coding and lncRNAs co-expression network increases our understanding of lncRNAs in biological network. ESCCAL-1 is a novel putative onco-lncRNA in esophageal cancer development.

23 August 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
RNRoseane Galdioli Nava
Roseane Galdioli Nava
AAAnny Silva Adri
Anny Silva Adri
IFIgor Salerno Filgueiras
Igor Salerno Filgueiras
ANAdriel Leal Nóbile
Adriel Leal Nóbile
PBPedro Marçal Barcelos
Pedro Marçal Barcelos
OMOtavio Marques
Otavio Marques
Major Depressive Disorder (MDD) is increasingly recognized as a neuroinflammatory condition characterized by dysregulated cytokine networks. This comprehensive review examines the immunomodulatory effects of antidepressant medications, revealing their significant impact on Th1/Th2 cytokine balance beyond their classical neurotransmitter actions. Clinical data show that diverse antidepressant classes consistently demonstrate immunomodulatory properties that extend beyond their classical neurotransmitter effects. These medications reduce pro-inflammatory markers (IFN-γ, TNF-α, IL-6) while enhancing anti-inflammatory cytokines (IL-10, TGF-β), effects particularly relevant for treatment-resistant cases with elevated baseline inflammation. The therapeutic potential of these immunoregulatory effects is supported by emerging interventions, including low-dose IL-2 immunotherapy, vagus nerve stimulation, and microbiota-targeted therapies, which show promise for specific depression subtypes. Importantly, these approaches appear most effective when guided by inflammatory biomarkers, suggesting a path toward personalized treatment strategies. By integrating findings from clinical studies and translational research, this work establishes immune modulation as a fundamental component of antidepressant action. The review provides a framework for developing next-generation treatments that target neuroimmune pathways in MDD, with particular emphasis on practical applications for treatment-resistant cases. These insights bridge the gap between neuropharmacology and clinical psychiatry, offering new therapeutic possibilities for patients with inflammation-associated depression.

15 April 2009 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MCMauro Castro
Mauro Castro
JRJosé Luiz Rybarczyk-Filho
José Luiz Rybarczyk-Filho
Rodrigo DalmolinRodrigo Dalmolin
Rodrigo Dalmolin
MSMarialva Sinigaglia
Marialva Sinigaglia
JMJosé C. F. Moreira
José C. F. Moreira
RARita De Almeida
Rita De Almeida
ViaComplex is an open-source application that builds landscape maps of gene expression networks. The motivation for this software comes from two previous publications (Nucleic Acids Res., 35, 1859–1867, 2007; Nucleic Acids Res., 36, 6269–6283, 2008). The first article presents a network-based model of genome stability pathways where we defined a set of genes that characterizes each genetic system. In the second article we analyzed this model by projecting functional information from several experiments onto the gene network topology. In order to systematize the methods developed in these articles, ViaComplex provides tools that may help potential users to assess different high-throughput experiments in the context of six core genome maintenance mechanisms. This model illustrates how different gene networks can be analyzed by the same algorithm. Availability:http://lief.if.ufrgs.br/pub/biosoftwares/viacomplex Supplementary information: Supplementary data are available at Bioinformatics online. Contact:mauro@ufrgs.br or rita@if.ufrgs.br

1 August 2003 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
FKFábio Klamt
Fábio Klamt
FDFelipe Dal-Pizzol
Felipe Dal-Pizzol
RRRafael Roehrs
Rafael Roehrs
RORamatis Birnfeld de Oliveira
Ramatis Birnfeld de Oliveira
Rodrigo DalmolinRodrigo Dalmolin
Rodrigo Dalmolin
JMJosé Cláudio Fonseca Moreira
José Cláudio Fonseca Moreira